No Detail Found!

Efficacy of High Dose Allopurinol in Reducing Left Ventricular Mass in Patients with Left Ventricular Hypertrophy by Comparing its Efficacy with Febuxostat - a Randomized Controlled Trial.

Author(s)
Balwant Lal Mayo Hospital, Lahore, Pakistan
Adil Iqbal Department of Medicine, King Edward Medical University, Lahore, Pakistan
Nasir Farooq Butt Department of Medicine, King Edward Medical University, Lahore, Pakistan
Fawad Ahmad Randhawa Department of Endocrinology, King Edward Medical University, Lahore, Pakistan
Rabia Rathore Department of Medicine, King Edward Medical University, Lahore, Pakistan
Tariq Waseem Department of Medicine, King Edward Medical University, Lahore, Pakistan
Abstract
Objective: To determine the efficacy of high-dose allopurinol in reducing left ventricular mass in patients with left ventricular hypertrophy by comparing its efficacy with febuxostat. Methods: The randomised controlled interventional study was conducted at Mayo Hospital, Lahore, Pakistan, from April to December 2015, comprising patients with left ventricular hypertrophy on echocardiography. They were randomly divided into two equal groups, with Group A receiving allopurinol and Group B receiving febuxostat. Primary endpoint was reduction in left ventricular mass and left ventricular mass index as calculated by echocardiography. Patients were followed at third and sixth month of enrolment to detect regression. Patients were investigated for eosinophil's count, urine for micro albuminuria and renal function tests to monitor side effects of allopurinol. SPSS 20 was used for data analysis. Results: There were 76 patients divided into two groups of 38(50%) each. Mean reduction in left ventricular mass between baseline and at six months in Group A and Group B was 35.474±13.54 and 21.921±3.33 respectively (p=0.0001) while mean reduction in left ventricular mass index between baseline and at six months was 17.26±4.36 and 17.63±21.07 respectively (p=0.0001). Greater improvement was observed in Group A. Conclusion: Allopurinol was found to be more effective than febuxostatin reducing the left ventricular mass and left ventricular hypertrophy independent of blood pressure.
Publication Details
Page(s) 1446-1450
DOI DOI not available
Published Journal: Journal of Pakistan Medical Association, Volume: 68, Issue: 10, Year: 2018

Request the full text from PASTIC

Keywords
Left ventricular mass index., Febuxostat, Left ventricular mass
References
SantulliG., 2013.Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts,J Cardiovasc Dis Res 1 1 -2
ArthamSM,LavieCJ,MilaniRV,PatelDA,VermaA,VenturaHO., 2009.Clinical impact of left ventricular hypertrophy and implications for regression,Prog Cardiovasc Dis 52 153 -67
LiebW,XanthakisV,SullivanLM,AragamJ,PencinaMJ,LarsonMG, 2009.Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the Framingham offspring study,Circulation 119 3085 -92
ChengS,FernandesVR,BluemkeDA,McClellandRL,KronmalRA,LimaJA, 2009.Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: The Multi-Ethnic Study of Atherosclerosis,Circ Cardiovasc Imaging 2 191 -8
PierdoenicoSD,CuccurulloF, 2010.Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis,Am J Hypertens 23 876 -81
DubeyTN,PaithankarU,YadavBS, 2016.Correlation of echocardiographic left ventricular mass index and electrocardiographic left ventricular hypertrophy variables,Int J Contemp Med Res 3 1287 -9
JainA,McClellandRL,PolakJF,SheaS,BurkeGL,BildDE, 2011.Cardiovascular imaging for assessing cardiovascular risk in asymptomatic men versus women: the Multi-Ethnic Study of Atherosclerosis(MESA),Circ Cardiovasc Imaging 4 8 -15
GargS,de LemosJA,AyersC,KhouriMG,PandeyA,BerryJD, 2015.Association of a 4-Tiered Classification of LV Hypertrophy With Adverse CV Outcomes in the General Population,JACC Cardiovasc Imaging 8 1034 -41
AlexescuTG,CozmaA,Sitar-TautA,NegreanV,HandruMI,MotocuM, 2016.Cardiac Changes in Overweight and Obese Patients,Rom J Intern Med 54 161 -72
LorellBH,CarabelloBA,Prognosis, 2000.,Circulation 102 470 -9
KaoMP,AngDS,GandySJ,NadirMA,HoustonJG,LangCC, 2011.Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease,J Am Soc Nephrol 22 1382 -9
TakimotoE,KassDA, 2007.Role of oxidative stress in cardiac hypertrophy and remodelling,Hypertension 49 241 -8
KelleyEE,KhooNK,HundleyNJ,MalikUZ,FreemanBA,TarpeyMM, 2010.Hydrogen peroxide is the major oxidant product of xanthine oxidase,Free Radic Biol Med 48 493 -8
XuX,HuX,LuZ,ZhangP,ZhaoL,WessaleJL, 2008.Xanthine oxidase inhibition with febuxostat attenuates systolic overloadinduced left ventricular hypertrophy and dysfunction in mice,J Card Fail 14 746 -53
RekhrajS,GandySJ,SzwejkowskiBR,NadirMA,NomanA,HoustonJG, 2013.High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease,J Am Coll Cardiol 61 926 -32
SagorMA,TabassumN,PotolMA,AlamMA, 2015.Myocardial Damage in Isoproterenol Induced Aged Rats,Oxid Med Cell Longev 478039 -
2010.,Nucleosides Nucleotides Nucleic Acids 29 306 -13
Schillaci G., 2004.Pharmacogenomics of left ventricular hypertrophy reversal: beyond the "one size fits all" approach to antihypertensive therapy,J Hypertens 22 2273 -5
LindholmLH,IbsenH,DahlöfB,DevereuxRB,BeeversG,de FaireU, 2002.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol,Lancet 359 1004 -10
2014.associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patient's independent of blood pressure reduction - A LIFE review,J Electrocardiol 47 630 -5
2006.,Circulation 114 2508 -16
TakimotoE,KassDA, 2007.Role of oxidative stress in cardiac hypertrophy and remodelling,Hypertension 49 241 -8
2002.Role of oxidative stress in myocardial hypertrophy and failure,J Mol Cell Cardiol 34 379 -88
CingolaniHE,PlastinoJA,EscuderoEM,MangalB,BrownJ,PérezNG, 2006.The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study,J Card Fail 12 491 -8
SzwejkowskiBR,GandySJ,RekhrajS,HoustonJG,LangCC,MorrisAD, 2013.Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy,J Am Coll Cardiol 62 2284 -93
HmarRC,KannangaraDR,RamasamySN,BaysariMT,WilliamsKM,DayRO, 2015.Understanding and improving the use of allopurinol in a teaching hospital,Intern Med J 45 383 -90
0

Citations

0

Downloads

124

Views